Summary
The study was carried out to determine the effect of a combination regimen of a small dose of calcitonin added to conjugated estrogens with medroxyprogesterone acetate on vertebral bone mass in early postmenopausal women. Comparisons were made with groups of women on calcitonin alone, on conjugated estrogens with medroxyprogesterone acetate alone, or on no treatment. The study was carried out over a 2-year period. The results of the study suggest that the combined regimen of calcitonin and estrogens increased vertebral bone mass in early postmenopausal women to a greater extent than calcitonin alone or estrogen alone. Increases in vertebral bone mass of 11.2% after 1 year and 9.2% after 2 years were demonstrated using the combined regimen. Both estrogens alone and calcitonin alone were, however, very effective in preventing rapid bone loss in the postmenopausal women studied.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Melton LJ, Kan SH, Frye MA, et al (1989) Epidemiology of vertebral fractures in women. Am J Epidemiol 129:1000–1011
Cummings SR, Kelsey JL, Nevitt MC, O'Dowd KJ (1985) Epidemiology of osteoporotic fractures. Epidemiol Rev 7:178–208
Lindsay R, Cosman F (1990) Epidemiology of osteoporosis. In: Drife JO, Studd JWW (eds) HRT and osteoporosis. Springer-Verlag, London, pp 75–85
Melton LJ (1988) Epidemiology of fractures. In: Riggs BL, Melton LJ III (eds) Osteoporosis: etiology, diagnosis and management. Raven Press, New York, pp 133–154
Horsman A, Gallagher JC, Simpson M, Nhordin BEC (1977) Prospective trial of oestrogen and calcium in postmenopausal women. Br Med J 2:789–792
Ettinger B, Genant HK, Cann CE (1985) Long term estrogen replacement prevents bone loss and fracture. Ann Intern Med 102:319–324
Weiss NS, Carol PH, Ure CL, Ballard JC, Williams AR, Darling JR (1980) Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195–1198
Burch JC, Byrd BF, Vaughn WK (1974) The effects of long-term estrogen on hysterectomised women. Am J Obstet Gynecol 118:778–782
Lindsay R, Aitken JM, Anderson JB, Hart DM, MacDonald EB, Clark AC (1976) Long term prevention of postmenopausal osteoporosis by oestrogen. Lancet i:1038–1041
Lindsay R, Hart DM, Purdie P, Ferguson MM, Clark AC, Kraszewski A (1978) Comparative effects of oestrogen and progestagen on bone loss in postmenopausal women. Clin Sci Molec Med 54:193–195
Lindsay R, Hart DM, Clark DM (1984) The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 63:759–763
Aitken JM, Hart DM, Lindsay R (1973) Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 111:515–518
Ross RK, Paganini-Hill A, Mach JM (1984) Reduction in fractures and other effects of oestrogen replacement therapy in human population. Osteoporosis proceedings of the Copenhagen International Symposium on Osteoporosis. 1:289–297
Stevenson JC, Abysekera G, Hillyard CJ et al (1981) Calcitonin and the calcium regulating hormones in postmenopausal women. Effect of oestrogens. Lancet 1:693–695
Overgaard K, Christiansen C (1991) Long term treatment of established osteoporosis with intranasal calcitonin. Calcif Tiss Int 49 Suppl:560–63
Gordon GS (1984) Prevention of bone loss and fractures in women. Maturitas 6:225
Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ III (1981) Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest 67:328–335
Eastell R, Wahner HW, O'Fallon M, Amadio PC, Melton LJ III, Riggs BL (1989) Unequal decrease in bone density of lumbar spine and ultradistal radius in Colles' and vertebral fracture syndromes. J Clin Invest 83:168–174
Natchigall LE, Natchigall KH, Natchigall RD, Beckman E (1988) Estrogen replacement therapy. A ten year prospective study in the response to Osteoporosis. Obstet Gynecol 53:277
Reginster JT, Denis D, Albert M (1988) Intranasal calcitonin. A new horizon in prevention. In: Gennazani AR, Petragliga F, Volpe A, Facchinetti F (eds) Gynaecological endocrinology. Parthenon Publishing Group, pp 593–601
MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJ (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet 18:900–902
Mazzuoli GF, Pacitti MT, Minisola J, Celi FS, Bianchi G (1990) Effects of salmon calcitonin (sCT) on bone loss induced by ovariectomy. In: Christiansen C, Overgaard K (eds) Osteoporosis. Aalbrod Aps Aalborg, Denmark, 2, pp 1255–1257
Overgaard K, Hansen MA, Jansen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. Br Med J 305:556–561
Savvas M, Studd JWW, Fogelman I, Dooley M, Montgomery J, Murby B (1988) Skeletal effects of oral estrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 297:331–333
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meschia, M., Brincat, M., Barbacini, P. et al. A clinical trial on the effects of a combination of elcatonin (Carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 53, 17–20 (1993). https://doi.org/10.1007/BF01352009
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01352009